

SMH
2021
ANTIBIOGRAM
Hospital-wide
(% Susceptible^a)

GRAM POSITIVE

GRAM NEGATIVE

Staphylococcus aureus	MSSA	MRSA	Enterococcus faecalis	Enterococcus faecium	Enterobacter cloacae ^b	Escherichia coli	Klebsiella pneumoniae	Proteus mirabilis	Acinetobacter baumannii group ^h	Pseudomonas aeruginosa
-----------------------	------	------	-----------------------	----------------------	-----------------------------------	------------------	-----------------------	-------------------	--	------------------------

This susceptibility chart is provided as a guide to empiric therapy until culture and susceptibility results are available.

R = Intrinsically resistant

= Susceptibility not tested

Number of Isolates	1432	1039	432	432	215	144	2037	358	144	25	270
---------------------------	-------------	-------------	------------	------------	------------	------------	-------------	------------	------------	-----------	------------

	GRAM POSITIVE					GRAM NEGATIVE					
	Staphylococcus aureus	MSSA	MRSA	Enterococcus faecalis	Enterococcus faecium	Enterobacter cloacae ^b	Escherichia coli	Klebsiella pneumoniae	Proteus mirabilis	Acinetobacter baumannii group ^h	Pseudomonas aeruginosa
Penicillins	Cloxacillin	71	100	R							
	Penicillin			R	94	7					
	Ampicillin/Amoxicillin			R	100	7	R	52	R	73	R
	Amoxicillin-Clavulanate	71	100	R			R	82	91	97	R
	Piperacillin-Tazobactam			R			67	96	94	99	91
Cephalosporins	Cephalexin ^c - 1st gen	71	100	R	R	R	R	77	91	96	R
	Cefazolin ^d - 1st gen	71	100	R	R	R	R	54	80	60	R
	Cefuroxime - 2nd gen			R	R	R					
	Cefixime - 3rd gen			R	R	R	31	78	91	96	
	Cefotaxime / Ceftriaxone - 3rd gen			R	R	R	61	80	92	97	R
	Ceftazidime - 3rd gen			R	R	R	65	84	93	99	78
Carbapenems	Ertapenem - restricted			R			91	100	98	100	R
	Imipenem - restricted			R							
	Meropenem - restricted			R			98	100	98	100	89
AMGs	Gentamicin						98	88	96	92	100
	Tobramycin						97	88	94	92	96
	Amikacin						100	100	99	100	100
FQs	Ciprofloxacin				68 ^g	3 ^g	93	55	86	79	100
	Levofloxacin	67	80	33	69 ^g	3 ^g					
	Moxifloxacin	67	81	33							
Miscellaneous	Erythromycin ^e	65	74	42	R	R					
	Clindamycin	81	82	77	R	R					
	Tetracycline ^f	90	95	76	21 ^g	18 ^g	90	74	85	R	91
	Linezolid - restricted	100	100	100	97	96					
	Nitrofurantoin-simple cystitis only ^g	99	98	100	99	21	48	97	35	R	R
	TMP-SMX or Cotrimoxazole	83	87	74	R	R	94	74	89	78	96
	Vancomycin	100	100	100	99	40					
Fosfomycin ^g					81	61	99	88	91		

NOTES:

a. This antibiogram includes only the first isolate of a specific organism from any patient.

b. These organisms carry an inducible β-lactamase and may develop resistance during prolonged therapy with 3rd generation cephalosporins.

c. Cephalexin susceptibility in gram-negatives is derived from urine isolates only and is predictive of cefazolin susceptibility.

d. Cefazolin susceptibility in gram-negatives is derived from nonurine isolates only and may underrepresent overall susceptibility.

e. Organisms susceptible to erythromycin are also susceptible to azithromycin/clarithromycin.

f. Organisms susceptible to tetracycline are also susceptible to doxycycline. However, some organisms that are nonsusceptible to tetracycline may be susceptible to doxycycline.

g. From urinary tract isolates only.

h. Small number of isolates, interpret results with caution.

† Data based on meningitis breakpoints

‡ Data based on non-meningitis breakpoints

Developed by:
Fraser Health Antimicrobial Stewardship
Program, Department of Medical Microbiology,
and Infection Prevention and Control